American College of Clinical Pharmacy
      Search      Cart
         

2024 ACCP/ASHP BCOP Clinical Sessions


Member Price:
$155.00
Nonmember Price:
$260.00

 

ASHP members, please visit www.rxcertifications.org to receive member pricing.

The 2024 ACCP/ASHP BCOP Clinical Sessions are part of the professional development programs for recertification of the Board-Certified Oncology Pharmacist® (BCOP) approved by the Board of Pharmacy Specialties (BPS) and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP).

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants' skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

Release Date: December 18, 2024
BCOP Deadline: December 16, 2025
ACPE Deadline: October 15, 2027

Technical Requirements:

Contents

BCOP Clinical Session
Treatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast Cancer

Hormone receptor-positive (HR+) breast cancer represents the majority (69%) of breast cancer cases. While comparatively, HER2+ and triple negative breast cancer spaces have seen a number of practice changing advancements in the past few years, HR+ breast cancer has seen relatively few until recently. Within both early-stage and metastatic settings of HR+ breast cancer, new FDA approvals have stirred an evolving treatment approach.

Newly approved treatments have the potential to cause significant toxicity and require pharmacists to be aware of specific preventative measures and monitoring parameters. Clinical controversies appear throughout this treatment setting given the rapidly evolving nature, particularly when it comes to treatment sequencing. This clinical session will assist pharmacists caring for this patient population to be well-versed in treatment nuances.

BCOP Clinical Session
Secondary School: Risk and Management of Secondary Malignancies in the Era of Targeted Therapies

Secondary malignancies caused by anticancer agents represent a spectrum of conditions that are both difficult to predict and difficult to treat. Specifically, myeloid-related secondary neoplasms are serious and have a poor prognosis. Conventional anticancer agents, like topoisomerase inhibitors and alkylating agents, have well-characterized risk of secondary malignancies due to their longevity in practice. However, in the era of targeted therapy, novel agents like poly-ADP ribose polymerase (PARP) inhibitors, carry meaningful risk of secondary malignancies; the incidence and risk-factors of which are only recently becoming elucidated due to their newness on the world market. Similarly, the treatment of secondary myeloid neoplasms has changed significantly given updates in classification and novel therapies to treat MDS and AML.

Part 1 of this session will focus on pathophysiology, preliminary and long-term data supporting clinical use, and risk of secondary malignancies with PARP inhibitors. Part 2 of this session will focus on the new classification of MDS and AML, with specific attention to the classification of secondary myeloid neoplasms. The session will discuss the shift towards underlying mutations and cytogenetic changes for the diagnosis and treatment of MDS and AML. Data on the presentation, biology, and outcomes of PARP inhibitor exposure-related MDS and AML will be discussed. Recommendations for the management of MDS and AML in a patient with previous PARP inhibitor will be discussed based on available evidence, where no current guidelines exist.

BCOP Clinical Session
Treatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast Cancer

Faculty

Farah Raheem, Pharm.D., BCOP

Clinical Oncology Pharmacist
Mayo Clinic
Phoenix, Arizona

Julia L. Ziegengeist, Pharm.D., BCOP

Clinical Pharmacist Coordinator, Breast Medical Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

BCOP Clinical Session
Secondary School: Risk and Management of Secondary Malignancies in the Era of Targeted Therapies

Faculty

Erin Hickey Zacholski, Pharm.D., BCOP

Assistant Professor, Pharmacotherapy and Outcomes Science
Virginia Commonwealth University (VCU)
School of Pharmacy
Clinical Pharmacy Specialist, Gynecologic Oncology
VCU Health
Richmond, Virginia

Kyle A. Zacholski, Pharm.D., BCOP

Clinical Pharmacy Specialist, Hematology & Oncology
Virginia Commonwealth University Health System
Clinical Assistant Professor
VCU School of Pharmacy
Richmond, Virginia

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of of BCOP.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.

Target Audience: These recertification activities are intended for the Board-Certified Oncology Pharmacist® (BCOP) and those interested in hormone receptor-positive breast cancer, and secondary malignancies in targeted therapies.

Contents

BCOP Clinical Session
Treatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast Cancer

Activity Number: 0217-9999-24-067-H01-P
Contact Hour(s): 2.00
Activity Type: Application Based

Learning Objectives

Treatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast Cancer

  1. Apply recent literature surrounding targeted therapy options in hormone receptor-positive (HR+), early-stage breast cancer.
  2. Identify characteristics of early-stage HR+ breast cancer patients most likely to benefit from targeted adjuvant therapy.
  3. Analyze literature regarding the integration of oral selective estrogen receptor degraders into current treatment guidelines.
  4. Recommend appropriate treatment strategies for patients who qualify to receive inhibitors of the PI3K/AKT pathway.
  5. Evaluate targeted treatment options beyond endocrine therapy for HR+ metastatic breast cancer.

BCOP Clinical Session
Secondary School: Risk and Management of Secondary Malignancies in the Era of Targeted Therapies

Activity Number: 0217-9999-24-068-H01-P
Contact Hour(s): 2.00
Activity Type: Application Based

Learning Objectives

Secondary School: Risk and Management of Secondary Malignancies in the Era of Targeted Therapies

  1. Assess clinical data evaluating the integration of PARP inhibitors into the treatment of breast, prostate, ovarian, and pancreatic cancers.
  2. Identify patients who are appropriate for initiation of PARP inhibitor therapy.
  3. Describe the pathophysiology, incidence, and risk factors of PARP inhibitor-associated secondary myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
  4. Summarize treatment paradigm changes with the updated classification of MDS and AML
  5. Design a treatment strategy for patients with MDS or AML with previous PARP inhibitor exposure.

Disclosures


Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.

Documents Click on a document to view/download.

BCOPCS24_Disclosures
BCOPCS24 Field Testers
BCOPCS24 Reviewers